Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Pharma
JPM26: Novo CEO outlines R&D, marketing tactics for 2026
During a presentation, Maziar Doustdar—who was tapped to lead Novo Nordisk last summer—didn’t hesitate to acknowledge the company’s “difficult 2025.”
Fraiser Kansteiner
Jan 14, 2026 10:05am
Lilly touts Zepbound-Taltz combo in patients with obesity, PsA
Jan 8, 2026 2:00pm
Viking, Aspen enlist commercial chiefs to prep for launches
Jan 7, 2026 11:18am
Lilly, J&J launches top Clarivate's Drugs to Watch 2026 report
Jan 7, 2026 9:28am
Novo rings in new year with US launch of Wegovy pill
Jan 5, 2026 10:45am
Novo's oral semaglutide is PCPs' most-anticipated obesity med
Dec 15, 2025 3:46pm
